Lappaconite HBr - CAS 97792-45-5
Catalog number: 97792-45-5
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Lappaconite Hydrobromide is a kind of alkaloid extracted from Aconitum sinomontanum Nakai and has anti-inflammatory effects.
Canonical SMILES:
1.Complexation of lappaconitine with glycyrrhizic acid: stability and reactivity studies.
Polyakov NE;Khan VK;Taraban MB;Leshina TV;Salakhutdinov NF;Tolstikov GA J Phys Chem B. 2005 Dec 29;109(51):24526-30.
NMR and UV-vis spectroscopy have been used to study the complexation of antiarrhythmic alkaloid lappaconitine with an efficient complexing agent from licorice, glycyrrhizic acid, which is known to profoundly influence the therapeutic activity of the alkaloid in the complex. In MeOH, DMSO, or aqueous solutions, lappaconitine has been shown to form a stable complex with glycyrrhizic acid with 1:1 stoichiometry over a broad concentration range from 1 microM to 300 microM. The stability constant K(11) equals 2.0 x 10(5) M(-1) in aqueous solution. A similar complex of lappaconitine hydrobromide--the pharmaceutical formulation used in the treatment of arrhythmia--is 2 orders of magnitude less stable than pure lappaconitine. A notable decrease in the rate of the photoinduced electron-transfer reaction between lappaconitine in a complex with glycyrrhizic acid and tyrosine allows the suggestion of an explicit interrelation between the suppressed chemical reactivity of the bound alkaloid and the changes of its therapeutic efficiency.
2.[The Study of Evidence Base for the Use of Lappaconitine Hydrobromide in Patients With Atrial Fibrillation].
Erlikh AD Kardiologiia. 2016 Mar;56(3):48-53.
Lappaconitine Hydrobromide (LH, allapinin) has been included by authors of National Guidelines on Diagnosis and Treatment of Atrial Fibrillation (AF), 2012 in the number of medications recommended for use in patients with AF for rhythm control. Moreover, LH is also included into the List of Vital and Essential Medicinal Drugs (VEMD) 2015. However, LH is not mentioned in corresponding guidelines of the European Society of Cardiology (ESC). Aim of the present review was to explore evidence base underlining use of LH in the context of AF and to understand reason for LH-related discrepancy between European and domestic guidelines.;RESULTS: ;Literature search has indicated that efficacy of LH was assessed only in small open studies. None of prospective trials included more than 100 patients. For more than 25 years of presence on the market slightly more than 400 patients were administered LH in clinical studies. In the only trial, designated as randomized number of participants (only men younger than 60 years) was small and the comparator was quinidine that presently is not used for maintenance of sinus rhythm in AF. Another study referenced in domestic guidelines on management of AF was observational and not intended for comparison of antiarrhythmic activity of drugs.
3.Pharmacokinetic study of lappaconitine hydrobromide in mice by LC-MS.
Wang Q;Li ZJ;Sun L;Gao LY;Li MH;Hao JJ;Zhang X;Sun YM Yao Xue Xue Bao. 2011 Apr;46(4):432-7.
A high sensitive and rapid method was developed for the analysis of lappaconitine in mouse plasma using liquid chromatography coupled to mass spectrometry (LC-MS). Detection was performed by positive ion electrospray ionization (ESI) in multiple reaction monitoring (MRM) mode, monitoring the transitions m/z 585 --> m/z 535 and m/z 356 --> m/z 192, for the quantification of lappaconitine and tetrahydropalmatine (internal standard, IS), respectively. The method was linear over the concentration range of 3.0-2000.0 ng x mL(-1). The lower limit of quantification was 3.0 ng x mL(-1). Intra- and inter-run precisions (RSD) were both less than 9.9% and accuracy (RE) within +/- 4.8%. After single intravenous injections of lappaconitine hydrobromide at 1.0, 2.0 and 4.0 mg x kg(-1), the elimination half-lives (t(1/2)) were 0.47, 0.48 and 0.49 h, and the areas under the curve (AUC(0-t)) were 55.5, 110.5 and 402.9 ng x h x mL(-1), separately. The pharmacokinetic profile of lappaconitine was linear at relatively lower dose levels (1.0-2.0 mg x kg(-1)). When the dose increased farther to 4.0 mg x kg(-1), the Vz and CL decreased, and the increase fold of the AUC was much larger than that of the dose.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

(CAS: 1337883-32-5)

DiZPK, a photocrosslinking amino acid, could be significant in revealling the physiological and functions of some proteins acting as a genetically encoded.

CAS 7492-32-2 Isopropamide

(CAS: 7492-32-2)

Isopropamide is a long-acting anticholinergic drug. It can be used for the treatment of peptic ulcers and other gastrointestinal disorders including hyperacidit...

CAS 39492-01-8 Gabexate Mesylate

Gabexate Mesylate
(CAS: 39492-01-8)

Gabexate mesylate is a serine protease inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation, and as a regiona...

(CAS: 252557-97-4)

Z-Ile-Glu-Pro-Phe-Ome is a peptide inhibitor of human heart chymase which is a chymotrypsin-like enzyme that converts angiotensin I to angiotensin II.

CAS 470-37-1 Cinobufagin

(CAS: 470-37-1)

Cinobufagin can inhibit the proliferation of U-2OS cells, and induce cell apoptosis. The potential mechanism of Cinobufagin-induced apoptosis may be related to ...

CAS 142642-31-7 PD 138142

PD 138142
(CAS: 142642-31-7)

PD 138142 is a water soluble Sterol O-acyltransferase inhibitor. Triacylglycerol secretion is decreased in the presence of PD-138142-15. Preclinical development...

CAS 321915-72-4 Albitiazolium bromide

Albitiazolium bromide
(CAS: 321915-72-4)

Albitiazolium bromide is a choline analogue acts as a cholinergic receptor antagonists, inhibits choline transport into Plasmodium-infected erythrocytes, thus p...

CAS 342785-41-5 FR-202306

(CAS: 342785-41-5)

FR-202306 is a synthetic peptide deformylase (PDF) inhibitor.

(CAS: 1286754-10-6)

This molecular is a sulfhydryl and amine reactive heterofuncational PEG linker. The chemical bonds that formed through Maleimide-PEG4-NHS linker are very stable...

CAS 1228280-29-2 KY 05009

KY 05009
(CAS: 1228280-29-2)

KY 05009 is an inhibitor of Traf2- and Nck-Interacting Kinase (TNIK; Ki value 100 nM in ATP competitive assay) that attenuates TGF-β1-mediated Wnt and Smad sign...

CAS 118525-36-3 Sagittatoside B

Sagittatoside B
(CAS: 118525-36-3)

Sagittatoside B is a natural compound isolated from traditional Chinese herb Yinyanghuo (Herba Epimdii).

(CAS: 100325-51-7)

CP-67015 has inhibitory effect on topoisomerase function. It is a direct-acting mutagen in mammalian cells with both gene and chromosomal level effects.

CAS 35449-36-6 Gemcadiol

(CAS: 35449-36-6)

Gemcadiol is a new antilipemic drug with lipid-regulating properties.

CAS 27200-12-0 Dihydromyricetin

(CAS: 27200-12-0)

Dihydromyricetin (Ampelopsin, Ampeloptin) is a natural antioxidant flavonoid from Ampelopsis grossedentata.

(CAS: 874119-13-8)

GSK317354A is a G-Protein-Coupled Receptor Kinase 2 (GRK2) inhibitor,but no detailed information has been published yet.

Protease-Activated Receptor-4

Protease-Activated Receptor-4, a member of the PARs family, is activated by thrombin, trypsin and cathepsin G but also is the agonist o fproteinase-activated re...

CAS 504-03-0 Nanofin

(CAS: 504-03-0)

Nanofin is neuropathic blocker used for mild to moderate hypertension.

CAS 882697-00-9 Anle138b

(CAS: 882697-00-9)

Anle138b is a novel fluorescent oligomer modulator and an aggregation inhibitor. In vitro, anle138b blocked the formation of pathological aggregates of prion pr...

CAS 1786-81-8 Prilocaine hydrochloride

Prilocaine hydrochloride
(CAS: 1786-81-8)

Prilocaine hydrochloride is a local anesthetic of the amino amide type.

LY 135305
(CAS: 123199-75-7)

LY 135305 is a bio-active molecular under the development of Eli Lilly. It can inhibit spontaneous lung metastasis in a dose-dependent manner.

Chemical Structure

CAS 97792-45-5 Lappaconite HBr

Quick Inquiry

Verification code

Featured Items